{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000239","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.198904+00:00","generated_at":"2026-06-20T19:50:19.448191+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rani Therapeutics reports ~$99M cash; FDA feedback supports 505(b)(2) pathway for RT-102; Phase 2 in H2 2023","bullets":["Preliminary cash, cash equivalents, restricted cash equivalents and marketable securities of ~$99M as of Dec 31, 2022, subject to audit.","FDA pre-IND feedback indicates 505(b)(2) pathway suitable for RT-102 (oral PTH analog for osteoporosis); Phase 2 trial expected H2 2023.","Positive topline Phase 1 repeat-dose results for RT-102 announced in Dec 2022, meeting all endpoints.","Plans to initiate three additional Phase 1 studies in 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypoparathyroidism), RT-111 (ustekinumab biosimilar)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000239","json":"https://secwatch.observer/filing/0000950170-23-000239.json","markdown":"https://secwatch.observer/filing/0000950170-23-000239.md","text":"https://secwatch.observer/filing/0000950170-23-000239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/0000950170-23-000239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/rani-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:50:19.448191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}